Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine
Up to 15 patients over the age of 18 years with a diagnosis of LEMS are eligible to enroll
if they are medically stable. They may receive 3,4 diaminopyridine in addition to other
treatments and standard of care investigations for LEMS under supervision of the primary
investigator. Safety laboratory studies and EKGs will be obtained.
The study has been approved by the University of Pittsburgh IRB. There is a local
Data-Safety Monitoring Board.
United States: Food and Drug Administration